Minovia Therapeutics receives FDA fast track for MNV-201 in MDS

Minovia Therapeutics Ltd. said that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its investigational therapy, MNV-201, for the treatment of Myelodysplastic Syndrome (MDS), a serious age-related hematopoietic disease. The company said that this designation follows existing FDA Fast Track and Rare Pediatric Disease approvals for MNV-201 in Pearson Syndrome. […] The post Minovia Therapeutics receives FDA fast track for MNV-201 in MDS appeared first on Longevity.Technology.